

# **OVERVIEW OF BORDERLINE PERSONALITY DISORDER**

**John G. Gunderson, M.D.**

# Before 1970

**From Untreatable  
Patients to Personality  
Organization: “A  
Psychoanalytic  
Colloquialism”**



# **CONTRIBUTIONS FROM EARLY PSYCHOANALYTIC WRITINGS**

- **lapses in reality testing**
- **“stable instability”**
- **transitional object relatedness**
- **the unstable disturbed sense of self**
- **abandonment fears**
- **reliance on splitting, other primitive defenses**



**1970 – 1980**

**From Personality Organization  
to Syndrome: “An Adjective in  
Search of a Noun”:**

**Descriptive Psychiatry and  
Psychopharmacology**

Vol. 132 No. 1 January 1975

**THE AMERICAN JOURNAL  
OF PSYCHIATRY**

*In this issue*

**John G. Gunderson and  
Margaret T. Singer on  
Defining Borderline Patients**

**OFFICIAL JOURNAL OF THE  
AMERICAN PSYCHIATRIC ASSOCIATION**


## **Treatment Dilemmas Predicted by the Borderline Syndrome**

- **Dramatic fluctuations in phenomenology and psychological capacities will challenge diagnostic certainty.**
- **Urgent appeals for an exclusive helping relationship will generate strong countertransference responses, often involving rescue efforts that prove to be inadequate.**
- **Treaters and others will have intense and distinct reactions, seeing the patient as a deprived waif or as an angry bully.**
- **Separation experiences (or decreased structure) will prompt behavioral (self harm) and cognitive (psychotic-like) regressions.**
- **Neither psychoanalysis nor drugs will help significantly and will often be harmful.**

# BPD's Pejorative Attributions

- “frequent flyers”
- “help-rejecting complainers”
- intractable, treatment resistant
- irresponsible, fickle, egocentric
- “emotional hypochondriacs”  
(attention-seeking)
- iatrogenic

I DON'T FEEL LIKE WE'RE  
MAKING MUCH PROGRESS  
WITH MY ABANDONMENT  
ISSUES, DOCTOR...






**1980 – 1990**

**From Syndrome to  
Personality Disorder:  
“Wisdom Is Never Calling a  
Patient Borderline”:**

**Testing Validity**



**ORGANIZATION**  
(PSYCHOANALYTIC)



**SYNDROME**  
(DESCRIPTIVE)



**DISORDER**  
(ETIOLOGY/Rx)

# BPD's Discrimination From Other Disorders

	Schizophr	MDD	PTSD	Bip D
Descriptive	-	+/-	-	+/-
Course	-	-	-	-
Familiality	-	+/-	-	-
Treatment Response	+/-	-	-	-

---

From Gunderson & Phillips 1991; Gunderson & Sabo 1993; Koenigsburg et al. 2002; White et al 2003; Paris et al. 2007; Gunderson & Links 2008



## **BPD & Drug/Alcohol Abuse**

- ~ 50% of BPD patients have either alcohol or substance use disorders (CLPS, MSAD).
- ~ 50% of SUD patients have BPD (Trull 2000)
- ~ 45% of opium addict patients have BPD (Drake ' 05)
- Family history studies show strong aggregation with *impulse spectrum* disorders (notably alcohol/drug abuse) (White ' 08)

# PIONEERING RESEARCHERS

**N. Blum**

**J. Clarkin**

**R. Cowdry**

**J. Gunderson**

**O. Kernberg**

**J. Kroll**

**P. Links**

**A. Loranger**

**T. McGlashan**

**J. Oldham**

**C. Perry**

**E. Plakun**

**C. Schulz**

**L. Siever**

**K. Silk**

**P. Soloff**

**M. Stone**

**S. Torgersen**


**D. Westen**

**M. Zanarini**

**1990 - 2000**

**From Unwanted Personality  
Disorder to Disorder-Specific  
Treatability:**

**Biological Psychiatry**



# **DBT's Innovations**

- **Identification of goals**
- **Emphasis on skill building**
- **Therapist availability**
- **Therapist as coach**



# MBT's Innovations

- **An empirical developmental base**
- **A “not knowing” non-interpretive stance**
- **Applicable within institutions**

# Neurobiological Advances

- **MRI & PET studies demonstrate a hyperresponsive amygdala (“*bottom up*”) and impaired inhibition from the prefrontal cortex (“*top down*”)**
- **neurohormones such as oxytocin and opioids mediate BPD’s exaggerated fears of abandonment and rejection**



**2000 - 2010**

**Borderline Personality  
Disorder: “A Good-  
Prognosis Brain Disease”?:**

**Etiology**

# HERITABILITY

<b>Schizophrenia</b>	<b>85%</b>
<b>Bipolar</b>	<b>80%</b>
<b>ADHD</b>	<b>75%</b>
<b>BPD</b>	<b>52-68%</b>
<b>MDD</b>	<b>45%</b>
<b>Panic Disorder</b>	<b>40%</b>
<b>PTSD</b>	<b>30%</b>

## Prototypes of the Phenotypes for BPD

- **Emotional (“hyperbolic” temperament) Dysregulation**
  - **Fearful/angry, chronically depressed, dysphoric**
  - **Readiness to shift from anxiety to depression**
  - **Neurotics on Neuroticism**
- **Behavioral Dyscontrol**
  - **Acts without concern for consequences (often self-injurious)**
  - **Externalizes**
- **Interpersonal Hypersensitivity**
  - **Intolerant of aloneness**
  - **Insecure attachments characterized by longings for closeness and fears of rejection or abandonment**
- **Cognitive**
  - **distorted self-image, misattributions**
  - **unstable identity**


## McLean Family Study: Results and Interpretation

- **Common pathway is better fitting model than independent pathways\***
  - **Pattern of traits within individuals and families is best explained by an underlying liability of BPD**
    - **Heritability of 59% for liability**
- **Supports BPD as a unitary entity rather than simply a sum of components**

# Other Support

- **Twin studies using similar sectors support a common pathway model (Distel et al. 2010, Kendler et al., 2010)**
- **Factor analytic studies support a single factor solution (Fossati et al., 1999; Clifton & Pilkonis, 2007)**


# BPD's Longitudinal Course



\*From the Collaborative Longitudinal Study of Personality Disorders (unpublished)

\*\*From the McLean Study of Adult Development (Zanarini et al. AJP 2003; 160:274-283)

# Mean GAF Scores



# INTERACTIONS OF AXIS I WITH BPD

## Effect

## Co-Occurring Axis I Disorder

SUD

MDD

Bipolar

ED

↓ BPD  
Course

YES

?

NO

NO

↓ Axis I  
Course

YES

YES

YES

YES

↑ Med Use

?

YES

YES

?



## **BPD and Alcohol/Substance Abuse**


- **Active SUD can: a) cause false positive BPD dx, b) make tx of BPD unfeasible**
- **Co-occurring SUD slow time-to-remission of BPD more than any other Axis I disorder (Zanarini '06)**
- **BPD predicts SUD of all types (Fiske '08, Walter '09) opioids make BPD subjects euthymic not high (41% of buprenorphine seekers have BPD) (New & Stanley, '10)**
- **OD & BPD → increase suicide, high risk needle use, non-compliance with HIV care (Drake '05)**

Supplement to

THE AMERICAN JOURNAL OF

# PSYCHIATRY

**PRACTICE  
GUIDELINE** for the Treatment of  
Patients With Borderline  
Personality Disorder










# Books on borderline personality disorder, 1968-2008



Source. Library of Congress database, Oct, 2008

# The Present

**Awareness: “Borderline  
Personality Disorder Is to  
Psychiatry What  
Psychiatry Is to  
Medicine”**

**“It is essential to increase awareness of borderline personality disorder among people suffering from this disorder, their families, mental health professionals, and the general public by promoting education, research, funding, early detection, and effective treatments.”**

# NIMH RESEARCH FUNDS

<u>Disorder</u>	<u>Amount (millions)</u>	<u>% Population</u>
Schizophrenia	300	0.4%
Bipolar Disorder	100	1.6%
BPD	6	1.4-5.9%



# Research

- **There is a shortage of young BPD investigators**
  - **fellowships are needed**

# PIONEERING RESEARCHERS

**N. Blum (~ 70)**

**J. Clarkin (~ 75)**

**R. Cowdry (d)**

**J. Gunderson (~ 70)**

**O. Kernberg (~ 85)**

**J. Kroll (~ 75)**

**P. Links (~ 65)**

**A. Loranger (d)**

**T. McGlashan (~ 70)**

**J. Oldham (~ 70)**

**C. Perry (~ 70)**

**E. Plakun (~ 65)**

**C. Schulz (~ 70)**

**L. Siever (~ 65)**

**K. Silk (~ 70)**

**P. Soloff (~ 65)**

**M. Stone (~ 75)**


**S. Torgersen (~ 65)**

**D. Westen (~ 55)**

**M. Zanarini (~ 65)**

# Research

- **There is a shortage of young BPD investigators**
  - **fellowships are needed**
- **Cutting edges of research**
  - **Neuropeptides - ? pharmacotherapies**



*"Of course I love you—I'm  
programmed to love you. I'm a  
goddam lovebird."*

# Research

- **There is a shortage of young BPD investigators**
  - **fellowships are needed**
- **Cutting edges of research**
  - **Neuropeptides - ? pharmacotherapies**
  - **Risk markers in children - ? impulsivity, early interventions**
  - **Integrating tx of BPD & SUD**
  - **Social rehabilitation therapies**

**Borderline patients  
should be able to assume  
that professionals who  
treat them have been  
trained to do so.**

# Training

- **There is a shortage of clinicians trained to treat BPD**
- **Evidence-based-treatments such as DBT, MBT, or TFP require extensive training and an extended duration that make them unavailable and unfeasible**
- **General Psychiatric Management (GPM) is an EBT that may be more generalizable**
- **Life experience and revised family environments are strong allies for change**

# **BPD AS A VARIANT**

**If not of:**

**i) schizophrenia (1970' s)**

**ii) depression (1980' s)**

**iii) PTSD (1990' s)**

**iv) Bipolar disorder (2000' s)**

**perhaps;**

**v) normal personality**



## **REVISING THE BORDERLINE DIAGNOSIS FOR DSM-V: AN ALTERNATIVE PROPOSAL**

John G. Gunderson, MD

The changes in the borderline personality disorder (BPD) diagnosis proposed by the DSM-V personality disorder work group involve radical changes in format (prototype and dimensions) and descriptive characteristics (traits). Changes of this magnitude will create an unwelcome and potentially harmful discontinuity with the definition that has guided BPD research and the development of disorder-specific therapies. This paper offers an alternative proposal that was developed in collaboration with clinical and research leaders. It includes modification of existing criteria, use of a diagnostic algorithm based on phenotypes, and giving BPD a hierarchical relationship vis-à-vis other personality disorders. These changes are incremental, diminish overlap and heterogeneity, sustain clinical and research development, and will improve utilization.

Within a year after borderline personality disorder's (BPD) coming of age was celebrated by the American Journal of Psychiatry (Kernberg & Michaels, 2009; Oldham, 2009) and the American Psychiatric Association's Annual Meeting, the DSM-V Personality Disorder Work Group has proposed major changes in the BPD diagnosis (prototypes, traits, and dimensions; see [dsm5.org](http://dsm5.org)). A thoughtful consideration of such change is timely insofar as changes have been few despite an ever-expanding body of research (Blashfield & Intocchia, 2000; Gunderson, 2009). The BPD syndrome defined in DSM-III, III-R, and IV is frequently criticized for too much overlap with other personality disorders and its polythetic algorithm allows too much heterogeneity.

The proposed changes by the DSM-V work group radically alter a definition of BPD that has survived with minimal changes since it entered the DSM system 30 years ago and from which has come a body of knowledge

---

From McLean Hospital, Harvard Medical School.

This work was supported by National Institute of Mental Health (NIMH), Collaborative Longitudinal Personality Disorders Study (MH400122) and Family Study (MH400130).

The author was assisted by Igor Weinberg, PhD, and is deeply indebted to the many colleagues who offered encouragement, identified relevant research, and helped shape this proposal (see Appendix).

Address correspondence to John G. Gunderson, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478; E-mail: [jgunderson@mclean.harvard.edu](mailto:jgunderson@mclean.harvard.edu)

## **SIGNATORIES**

**Anthony Bateman, MD**

**Aaron T. Beck, MD**

**Donald W. Black, MD**

**Martin Bohus, MD**

**Lois W. Choi-Kain, MD**

**John F. Clarkin, PhD**

**Michael B. First, MD**

**Peter Fonagy, PhD**

**Glen O. Gabbard, MD**

**Marianne Goodman, MD**

**Perry D. Hoffman, PhD**

**Harold W. Koenigsberg, MD**

**Otto F. Kernberg, MD**

**Marc F. Lenzenweger, PhD**

**Marsha Linehan, PhD**

**Thomas H. McGlashan, MD**

**Antonia S. New, MD**

**Joel Paris, MD**

**Paul A. Pilkonis, PhD**

**Elsa F. Ronningstam, PhD**

**S. Charles Schulz, MD**

**Kenneth R. Silk, MD**

**Paul H. Soloff, MD**

**Barbara H. Stanley, MD**

**Timothy J. Trull, PhD**

**Mary C. Zanarini, EdD**

# IMPLICATIONS FOR DSM V

- **BPD's identity should be retained**
- **BPD should move to Axis I**
- **BPD should be legitimized for adolescents**
- **Criteria → phenotypes**

ORIGINAL PAPER

**Borderline Personality Disorder: Considerations for Inclusion in the Massachusetts Parity List of ‘Biologically-Based’ Disorders**

**Mary Ellen Foti • Jeffrey Geller • Laura S. Guy • John G. Gunderson • Brian A. Palmer • Lisa M. Smith**

Published online: 1 October 2010  
Springer Science+Business Media, LLC 2010

**Abstract:** Borderline Personality Disorder (BPD) is a common and severe mental illness that is infrequently included under state mental health parity statutes. This review considers BPD parity, using the Massachusetts mental health parity statute as a model. While BPD can co-occur with other disorders, studies of its heritability, diagnostic validity/reliability, and response to specific treatments indicate it is best considered an independent disorder, one that negatively impacts the patient's treatment response to comorbid disorders, particularly mood disorders. Persons with BPD are high utilizers of treatment, especially emergency departments and inpatient hospitalizations—the most expensive forms of psychiatric treatment. While some patients remain chronically symptomatic, the majority improve. The findings from psychopharmacologic and other biologic treatment data, coupled with associated brain functioning findings, indicate BPD is a biologicallybased disorder. Clinical data indicate that accurately diagnosing and treating BPD conserves resources and improves outcomes. Based on this analysis, insuring BPD in the same manner as other serious mental illnesses is well-founded and recommended.

**Keywords** Borderline personality disorder Mental health parity  
Biologically-based mental illness Mental health policy

---

M. E. Foti  
Massachusetts Department of Mental Health, Boston, MA, USA

J. Geller (&) L. S. Guy L. M. Smith  
Department of Psychiatry, Center for Mental Health Services Research, University of Massachusetts  
Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA  
e-mail: [jeffrey.geller@umassmed.edu](mailto:jeffrey.geller@umassmed.edu)

J. G. Gunderson  
The Center for Treatment of Borderline Personality Disorder, McLean Hospital, Harvard Medical  
School, Belmont, MA, USA

B. A. Palmer  
McLean Hospital, Harvard Medical School, Belmont, MA, USA